Immunoglobulin Patents (Class 536/23.53)
-
Publication number: 20140178935Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.Type: ApplicationFiled: October 2, 2013Publication date: June 26, 2014Applicant: AVEO PHARMACEUTICALS, INC.Inventors: William M. Winston, JR., S. Kirk Wright, May Han, Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris, Arnold Horwitz
-
Publication number: 20140179905Abstract: Anti-polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided.Type: ApplicationFiled: November 14, 2013Publication date: June 26, 2014Applicant: GENENTECH, INC.Inventors: Nathaniel C. Gordon, Robert F. Kelley, Anh Pham
-
Publication number: 20140178410Abstract: The present invention relates to an antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate, wherein the antibody or antibody fragment comprises a variable heavy chain (VH) domain and/or a variable light chain (VL) domain, and wherein—(a) the VH domain comprises an amino acid sequence that includes one, two or three complementarity determining regions (CDRs) selected from the group consisting of: a CDR1 sequence comprising an amino acid sequence having at least 25%, 50%, 75% or 100% sequence identity to the sequence of SEQ ID NO: 17; a CDR2 sequence comprising an amino acid sequence having at least 5%, 11%, 17%, 23%, 29%, 35%, 47%, 52%, 58%, 64%, 70%, 76%, 82%, 94% or 100% sequence identity to the sequence of SEQ ID NO: 18; and a CDR3 sequence comprising an amino acid sequence having at least 4%, 9%, 13%, 18%, 22%, 27%, 31%, 36%, 40%, 45%, 50%, 54%, 59%, 63%, 68%, 72%, 77%, 81%, 86%, 90%, 95% or 100% sequence identity to the sequence of SEQ ID NO: 19, 20, 21Type: ApplicationFiled: August 8, 2012Publication date: June 26, 2014Applicants: DYAX CORP., ATHERA BIOTECHNOLOGIES ABInventors: Knut Pettersson, Ola Camber, Dan Sexton, Andrew E. Nixon
-
Publication number: 20140178409Abstract: As discussed in detail herein, isolated epitope peptides derived from SEMA5B bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, pharmaceutical agents or compositions of this invention find particular utility in the treatment and/or prevention of cancers and tumors, including, for example, esophageal cancer, NSCLC, RCC and SCLC.Type: ApplicationFiled: June 7, 2012Publication date: June 26, 2014Applicant: OncoTherapy Science, Inc.Inventors: Takuya Tsunoda, Ryuji Osawa, Sachiko Yoshimura, Tomohisa Watanabe, Gaku Nakayama, Yusuke Nakamura
-
Publication number: 20140178936Abstract: Disclosed are CD70 binding agents, such as humanized anti-CD70 antibodies and fragments and derivatives, that exert a cytotoxic, cytostatic or immunomodulatory on CD70 expressing cells, as well as pharmaceutical compositions and kits comprising the antibody, fragment or derivative. Also disclosed are methods for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the CD70 binding agents or pharmaceutical compositions.Type: ApplicationFiled: October 14, 2013Publication date: June 26, 2014Applicant: SEATTLE GENETICS, INC.Inventors: CHARLOTTE MCDONAGH, PAUL CARTER
-
Patent number: 8759494Abstract: The invention relates to antibodies to the tumor-associated antigen CD33 and to the use thereof for immunotargeting CD33-positive cells. The antibodies according to the invention are suitable for use in the field of medicine, pharmaceuticals, and biomedical research. According to the invention, the aim is achieved by means of novel anti-CD33 antibodies comprising the complementary determining regions (CDRs) defined in the claim. The antibodies according to the invention are characterized by a high affinity for human CD33, of the order of magnitude of 10?10 mol/l. The CDR sequences according to the invention are suitable in particular for producing recombinant fragments (such as scFv fragments or bispecific antibodies) and for immunotargeting, due to the high affinity thereof.Type: GrantFiled: September 22, 2010Date of Patent: June 24, 2014Assignee: GEMoaB Monoclonals GmbHInventors: Michael Bachmann, Slava Stamova
-
Patent number: 8759025Abstract: The present invention relates to humanized antibodies binding to CD47; diabodies binding to human CD47, characterized in that a disulfide bond exists between diabody-forming fragments; genes encoding any one of said antibodies; vectors containing said genes; host cells containing said vectors; processes for preparing antibodies comprising the step of culturing said host cells; and therapeutic agents for hematological disorders comprising said antibodies.Type: GrantFiled: December 19, 2011Date of Patent: June 24, 2014Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Yasufumi Kikuchi, Shinsuke Uno, Yasuko Kinoshita, Shigeyuki Iijima, Naoshi Fukushima, Masayuki Tsuchiya
-
Publication number: 20140170154Abstract: Antibodies to human IL-23R are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.Type: ApplicationFiled: February 14, 2014Publication date: June 19, 2014Applicant: MERCK SHARP & DOHME CORP.Inventor: Leonard G. Presta
-
Publication number: 20140171623Abstract: The present invention relates to novel molecules (Fc variants) comprising at least one antigen binding region and an Fc region that further comprises a modified hinge which alters the binding of Fc to one or more Fc ligand (e.g., Fc?Rs) and/or modulates effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc?R and/or C1q. Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variants particularly for therapeutic purposes.Type: ApplicationFiled: February 17, 2014Publication date: June 19, 2014Applicant: MedImmune, LLCInventors: William Dall'Acqua, Herren Wu, Melissa Damschroder, Jose Casas-Finet
-
Publication number: 20140170136Abstract: A method of preparing an antibody suitable for use in an equine is provided. Also provided are equinised antibodies which specifically bind to equine neuronal growth factor (NGF) and neutralise the ability of equine NGF to bind to the p75 or TrkA equine NGF receptor. The invention extends to nucleic acids encoding same and to methods of treating pain and arthritis in an equine using said antibodies and/or nucleic acids.Type: ApplicationFiled: May 8, 2012Publication date: June 19, 2014Inventor: David Gearing
-
Publication number: 20140170681Abstract: The present invention provides a novel, isolated anti-CXCR4 antibody for use in the diagnosis of cancer.Type: ApplicationFiled: July 30, 2012Publication date: June 19, 2014Inventors: Christine Klinguer-Hamour, Alexandra Jouhanneaud, Marie-Claire Janin-Bussat
-
Publication number: 20140170114Abstract: The present invention relates to compositions and methods for diagnosing and treating diseases, disorders or conditions associated with dysregulated expression of GPC3. The invention provides novel antibodies that specifically bind to glypican-3 (GPC3). The invention also relates to a fully human chimeric antigen receptor (CAR) wherein the CAR is able to target GPC3.Type: ApplicationFiled: February 17, 2014Publication date: June 19, 2014Applicant: The Trustees of the University of PennsylvaniaInventor: David Kaplan
-
Publication number: 20140170170Abstract: Provided are a hybridoma cell CGMCC No. 4783 that secretes a monoclonal antibody of an anti-cyanobacteria cell surface antigen, and the secreted monoclonal antibody thereof. Also provided are an anti-cyanobacteria recombinant antibody poly-peptide, encoding gene, preparation method and use thereof. The anti-cyanobacteria recombinant antibody polypeptide is composed of an anti-cyanobacteria antibody mimetic polypeptide operably linearly connecting to the carboxyl terminal of an Escherichia coli polypeptide. The anti-cyanobacteria antibody mimetic polypeptide is a polypeptide with cyanobacteria identifying and binding cap-ability designed based on an antigen binding fragment of the monoclonal antibody secreted by the CGMCC No.4783 hybridoma cell. The anti-cyanobacteria recombinant antibody polypeptide directly form an ion channel on the cell membrane of a cyanobacteria to kill the cyanobacteria, targeted killing the cyanobacteria (prokaryote) without killing other beneficial eukaryotic cell algae.Type: ApplicationFiled: March 27, 2012Publication date: June 19, 2014Applicant: Protein Design Lab,LtdInventor: Xiaoqing Qiu
-
Publication number: 20140171634Abstract: The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF?, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF?, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNF?-related disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: ApplicationFiled: February 20, 2014Publication date: June 19, 2014Applicant: ESBATech, an Alcon Biomedical Research Unit LLCInventors: Stefan Ewert, Alcide Barberis, David M. Urech, Adrian Auf Der Maur, Peter Lichtlen
-
Publication number: 20140170163Abstract: Provided herein are methods of producing neutralizing monoclonal antibodies, by cyclical immunization, that cross-react with strains of Influenza virus of the same subtype or different subtypes. Also provided herein are compositions comprising such antibodies and methods of using such antibodies to diagnose, prevent or treat Influenza virus disease.Type: ApplicationFiled: January 23, 2014Publication date: June 19, 2014Applicant: MOUNT SINAI SCHOOL OF MEDICINEInventors: Adolfo Garcia-Sastre, Peter Palese, Taia T. Wang
-
Patent number: 8753637Abstract: A binding partner for the TSH receptor, which binding partner comprises, or is derived from, a human monoclonal or recombinant antibody, or one or more fragments thereof, reactive with the TSH receptor, uses thereof, methods of diagnosis and therapy employing the same, and anti-idiotypic antibodies thereto.Type: GrantFiled: December 28, 2011Date of Patent: June 17, 2014Assignee: RSR LimitedInventors: Jane Sanders, Jadwiga Furmaniak, Bernard Rees Smith
-
Patent number: 8753627Abstract: The disclosure provides compositions and methods relating to or derived from anti-activin A binding proteins, including antibodies. In particular embodiments, the disclosure provides fully human, humanized, and chimeric anti-activin A antibodies that bind human activin A, activin A-binding fragments and derivatives of such antibodies, and activin A-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having activin A-related disorders or conditions including cachexia related to gonadal cancer, other cancers, rheumatoid arthritis, and other diseases.Type: GrantFiled: July 16, 2012Date of Patent: June 17, 2014Assignee: Amgen Inc.Inventors: Hui-Quan Han, Qing Chen, Keith Soo-Nyung Kwak, Xiaolan Zhou
-
Patent number: 8753843Abstract: Engineered antibodies to human IL-17A are provided, as well as uses thereof.Type: GrantFiled: October 27, 2010Date of Patent: June 17, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Leonard G. Presta, Edward P. Bowman
-
Publication number: 20140162292Abstract: The present invention provides antibodies useful for diagnosing and treating tumors as well as methods of screening for antitumor agents. More specifically, tumors can be diagnosed and treated using an anti-phosphorylated p62 antibody that recognizes phosphorylation of serine at position 351 of an amino acid sequence of SEQ ID No. 1 or at a position corresponding thereto. An antitumor agent can be obtained by screening for a substance that inhibits the phosphorylation or that dephosphorylates the phosphorylated serine.Type: ApplicationFiled: June 5, 2013Publication date: June 12, 2014Inventors: Masaaki KOMATSU, Yoshinobu ICHIMURA
-
Publication number: 20140161828Abstract: The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates.Type: ApplicationFiled: December 5, 2013Publication date: June 12, 2014Applicant: AMGEN INC.Inventors: Richard J. ARMITAGE, Michelle BLAKE, William C. FANSLOW, III, Jason Charles O'NEILL, Gunasekaran KANNAN, Jiangchun XU, Mark Edward TOMETSKO
-
Publication number: 20140161796Abstract: The invention pertains to an isolated VH single domain antibody comprising a C-terminal modification, where the C-terminal modification comprises a deletion of at least one amino acid residue that eliminates the interaction of a pre-existing antibody with the single domain antibody without interfering with the binding of the single domain antibody with its target.Type: ApplicationFiled: September 13, 2013Publication date: June 12, 2014Inventors: Andreas LOEW, Hilmar EBERSBACH
-
Publication number: 20140161793Abstract: A conjugate molecule comprising an oligo- or polysaccharide covalently bound to a carrier and its use as potential vaccine against infection by S. Flexneri.Type: ApplicationFiled: December 14, 2011Publication date: June 12, 2014Applicants: INSERM, INSTITUT PASTEUR, Centre National De La Recherche ScientifiqueInventors: Armelle PHALIPON, Farida NATO, Laurence MULARD, Philippe SANSONETTI, Francoise BALEUX, Frederic BELOT, Cyrille GRANDJEAN
-
Publication number: 20140161875Abstract: This invention concerns affinity tools for oligomeric forms of tau protein. It relates to the field of neurodegeneration, more particularly to the field of tau-related diseases and tauopathy. The invention provides novel tau antibodies and antibody fragments, nucleic acids encoding such antibodies and antibody fragments, cell lines producing such antibodies and antibody fragments, antibody compositions, and kits for the detection of aggregated tau and for the diagnosis of diseases involving aggregated tau. The invention further provides methods for the detection of aggregated tau, for the diagnosis of diseases involving aggregated tau, and for the identification of compositions interfering with the formation and/or stability of tau aggregates.Type: ApplicationFiled: July 16, 2012Publication date: June 12, 2014Applicant: KATHOLIEKE UNIVERSITEIT LEUVENInventors: Joris Winderickx, Eugeen Vanmachelen, Fred Van Leuven
-
Publication number: 20140161800Abstract: The present invention relates to mono-specific and multi-specific polypeptide therapeutics that specifically target cells expressing prostate-specific membrane antigen (PSMA) and are useful for the treatment of prostate cancer (e.g., castrate-resistant prostate cancer), tumor-related angiogenesis or benign prostatic hyperplasia (BPH). In one embodiment, the multi-specific polypeptide therapeutics bind both PSMA-expressing cells and the T-cell receptor complex on T cells to induce target-dependent T-cell cytotoxicity, activation and proliferation.Type: ApplicationFiled: April 20, 2012Publication date: June 12, 2014Inventors: John W. Blankenship, Elaine Todd Sewell, Philip Tan
-
Publication number: 20140161822Abstract: The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same.Type: ApplicationFiled: November 12, 2013Publication date: June 12, 2014Applicant: Genentech, Inc.Inventors: Min XU, Mercedesz BALAZS, Ning CHAI, Nancy Chiang, Henry CHIU, Zhaoyu JIN, Zhonghua LIN, Patrick LUPARDUS, Gerald R. NAKAMURA, Hyunjoo PARK, Lee SWEM
-
Publication number: 20140162316Abstract: The present invention relates to antibodies reactive with GLP-1R, and methods of making and using them.Type: ApplicationFiled: February 5, 2013Publication date: June 12, 2014Applicant: Janssen Biotech, Inc.Inventors: Karyn O'Neil, Kristen Picha
-
Publication number: 20140161790Abstract: The present application relates to immunoglobulin compositions with improved half-life, and their application, particularly for therapeutic purposes.Type: ApplicationFiled: November 19, 2013Publication date: June 12, 2014Applicant: Xencor, Inc.Inventors: John Desjarlais, Gregory Alan Lazar
-
Patent number: 8747855Abstract: Provided are antibodies comprising an antigen recognition domain capable of binding an MHC molecule being complexed with a human immunodeficiency virus (HIV) peptide, wherein the antibody does not bind the MHC molecule in an absence of the complexed peptide, and wherein the antibody does not bind the peptide in an absence of the MHC molecule. Also provided are methods of using same for diagnosing HIV infection and treating AIDS.Type: GrantFiled: April 5, 2009Date of Patent: June 10, 2014Assignee: Technion Research & Development Foundation LimitedInventors: Yoram Reiter, Maya Haus-Cohen
-
Patent number: 8748175Abstract: Provided are antibodies specifically binding to the epidermal growth factor receptor (EGFR) which are effective for the treatment of EGFR-mediated cancers.Type: GrantFiled: November 2, 2009Date of Patent: June 10, 2014Assignee: Green Cross CorporationInventors: Se-Ho Kim, Ki Hwan Chang, Kwang-Won Hong, Yong-Won Shin, Min-soo Kim, Hae-Won Lee, Yong Nam Shin, Kyung Hwan Ryoo, Dong Hyuck Seo, Jong-Hwa Won, Min-Kyu Hur
-
Publication number: 20140154254Abstract: The present application is directed to heterodimeric antibodies and methods of use.Type: ApplicationFiled: November 21, 2013Publication date: June 5, 2014Applicant: AMGEN INC.Inventors: Gunasekaran Kannan, Monica Florio, Zhi Liu, Wei Yan
-
Publication number: 20140154255Abstract: The present disclosure relates to antibodies directed to vascular endothelial growth factor (“VEGF”) and uses of such antibodies, for example to treat diseases associated with the activity and/or overproduction of VEGF.Type: ApplicationFiled: November 26, 2013Publication date: June 5, 2014Applicant: AbbVie Biotherapeutics Inc.Inventor: Yoshiko AKAMATSU
-
Publication number: 20140154252Abstract: Variations on the structural themes for multivalent binding molecules with effector function, or scorpions, will be apparent to those of skill in the art upon review of the present disclosure, and such variant structures are within the scope of the invention.Type: ApplicationFiled: March 15, 2013Publication date: June 5, 2014Applicant: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLCInventors: PETER ARMSTRONG THOMPSON, JEFFREY A. LEDBETTER, MARTHA SUSAN HAYDEN-LEDBETTER, WILLIAM BRADY
-
Publication number: 20140154261Abstract: An object of the present invention is to prepare an antibody that targets CAPRIN-1 specifically expressed on the surface of cancer cells and is superior in antitumor activity to conventional antibodies and to provide use of the antibody as a therapeutic and/or preventive agent for cancer. The present invention provides use of an antibody targeting an identified cancer antigenic protein specifically expressed on the surface of cancer cells as a therapeutic and/or preventive agent for cancer, specifically, a pharmaceutical composition for treatment and/or prevention of cancer, comprising as an active ingredient an antibody or a fragment thereof which has immunological reactivity with a CAPRIN-1 protein, the antibody or the fragment thereof comprising a heavy chain variable region comprising amino acid sequences represented by SEQ ID NOs: 5, 6, and 7 and a light chain variable region comprising amino acid sequences represented by SEQ ID NOs: 9, 10, and 11.Type: ApplicationFiled: August 3, 2012Publication date: June 5, 2014Inventors: Fumiyoshi Okano, Shinichi Kobayashi, Yoshitaka Minamida, Takanori Saito
-
Publication number: 20140155581Abstract: Detailed herein are contiguous, multimeric, multispecific polypeptides, nucleic acids encoding such polypeptides, and methods for making such polypeptides and nucleic acids.Type: ApplicationFiled: July 2, 2012Publication date: June 5, 2014Inventors: Changshou Gao, Nazzareno Dimasi
-
Publication number: 20140155584Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.Type: ApplicationFiled: December 30, 2011Publication date: June 5, 2014Applicant: Takeda Pharmaceutical Company LimitedInventors: Kathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Gyorgy Pal Snell, Vinay Bhaskar
-
Publication number: 20140154267Abstract: Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 antagonist to a patient afflicted with such a condition. Suitable IL-4 antagonists include, but are not limited to, IL-4 receptors (such as a soluble human IL-4 receptor), antibodies that bind IL-4, antibodies that bind IL-4R, IL-4 muteins that bind to IL-4R but do not induce a biological response, molecules that inhibit IL-4-induced signal transduction, and other compounds that inhibit a biological effect that results from the binding of IL-4 to a cell surface IL-4R. Particular antibodies provided herein include human monoclonal antibodies generated by procedures involving immunization of transgenic mice. Such human antibodies may be raised against human IL-4 receptor. Certain of the antibodies inhibit both IL-4-induced and IL-13-induced biological activities.Type: ApplicationFiled: February 7, 2014Publication date: June 5, 2014Applicant: Immunex CorporationInventors: Richard J. ARMITAGE, Jose Carlos ESCOBAR, Arvia E. MORRIS, John D. PLUENNEKE
-
Publication number: 20140154245Abstract: The present invention provides a humanized anti-EMAP II antibody, the use of the humanized antibody, and pharmaceutical compositions containing the humanized antibody. The humanized anti-EMAP II antibody shows reduced immunogenicity and increased half-life while having similar or improved antigen binding capacity compared to the parent monoclonal antibody. Thus, the humanized anti-EMAP II antibody of the present invention can be more effectively used as a diagnostic reagent for EMAP II and a therapeutic agent for diseases that are mediated by EMAP II.Type: ApplicationFiled: July 14, 2011Publication date: June 5, 2014Applicants: L & K Biomed Co., Ltd., Cell & Bio Co., Ltd.Inventor: Kang-Jun Yoon
-
Publication number: 20140154250Abstract: The present disclosure relates to single-chain multivalent binding proteins, compositions comprising the single-chain multivalent binding proteins, and methods of making and using the single chain-multivalent binding proteins.Type: ApplicationFiled: March 15, 2013Publication date: June 5, 2014Applicant: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLCInventors: PETER ARMSTRONG THOMPSON, JEFFREY A. LEDBETTER, MARTHA SUSAN HAYDEN-LEDBETTER, WILLIAM BRADY
-
Publication number: 20140154268Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin ?5?1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-?5?1 antibodies or antigen binding portions thereof described herein.Type: ApplicationFiled: February 21, 2013Publication date: June 5, 2014Applicants: PFIZER INC., BRISTOL-MYERS SQUIBB COMPANYInventors: STEVEN LEE BENDER, GERALD FRIES CASPERSON, DANA DAN HU-LOWE, XIN JIANG, GANG LI, MICHAEL AIDAN NORTH, JIANYING WANG, GRANT WICKMAN, PETER BRAMS, HAICHUN HUANG, BRIGITTE DEVAUX, HAIBIN CHEN, DAWN M. TANAMACHI, KRISTOPHER TOY, LAN YANG, TIM W. SPROUL, MARK YAMANAKA
-
Publication number: 20140154744Abstract: Non-naturally occurring tRNASec and methods of using them for recombinant expression of proteins engineered to include one or more selenocysteine residues are disclosed. The non-naturally occurring tRNASec can be used for recombinant manufacture of selenocysteine containing polypeptides encoded by mRNA without the requirement of an SECIS element. In some embodiments, selenocysteine containing polypeptides are manufactured by co-expressing a non-naturally occurring tRNASec a recombinant expression system, such as E. coli, with SerRS, EF-Tu, SelA, or PSTK and SepSecS, and an mRNA with at least one codon that recognizes the anticodon of the non-naturally occurring tRNASec.Type: ApplicationFiled: July 11, 2012Publication date: June 5, 2014Applicant: YALE UNIVERSITYInventors: Dieter Soll, Caroline Aldag, Michael Hohn
-
Patent number: 8741298Abstract: The present invention provides antibodies that preferentially bind to an ApoE(1-272) fragment relative to ApoE(1-299). These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of neurological diseases.Type: GrantFiled: February 7, 2012Date of Patent: June 3, 2014Assignee: Neotope Biosciences LimitedInventors: Dale B. Schenk, Tarlochan S. Nijjar, Philip W. Payne, Robin Barbour
-
Patent number: 8742088Abstract: The present invention provides a nucleic acid which comprises a non-specific promoter and at least one sequence that encodes a polypeptide that has at least one heterologous T cell epitope therein but does not have any regulatory T cell epitopes. The polypeptide may be one chain of a heterodimer such as the heavy or light chain of an antibody molecule, the heterologous T cell epitope causing disruption of the heterodimer chain such that it cannot bind with the other chain of the heterodimer. The nucleic acid can be used to raise a T cell response against the at least one heterologous T cell epitope.Type: GrantFiled: September 24, 2009Date of Patent: June 3, 2014Assignee: Scancell LimitedInventors: Linda Gillian Durrant, Rachael Louise Metheringham, Victoria Anne Pudney
-
Patent number: 8742074Abstract: A variant of a parent polypeptide including an Fc region, which variant exhibits increased binding to FcRn as compared to the parent polypeptide and includes at least one amino acid modification in the Fc region.Type: GrantFiled: March 19, 2010Date of Patent: June 3, 2014Assignee: Laboratoire Francais du Fractionnement et des BiotechnologiesInventors: Christian Behrens, Sylvie Jorieux, Abdelhakim Kharrat, Khalil Bouayadi, Philippe Mondon, Celine Monnet-Mars
-
Patent number: 8741293Abstract: The present invention refers to human antibodies which are directed against ?-Synuclein (?-Syn) and their use in medicine and diagnosis.Type: GrantFiled: March 3, 2011Date of Patent: June 3, 2014Assignee: Dr. Rentschler Holding GmbH & Co. KGInventors: Richard Dodel, Michael Bacher, Daniela Besong Agbo, Sascha Hagemann, Monika Balzer-Geldsetzer, Bernd Rehberger, Renee Weber
-
Publication number: 20140147447Abstract: Compositions and methods are provided for treating diseases associated with CXCL13 expression, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CXCL13 monoclonal antibodies have been developed to neutralize CXCL13.Type: ApplicationFiled: September 1, 2011Publication date: May 29, 2014Applicant: VACCINEX, INC.Inventors: Ekaterina Klimatcheva, Mark Paris, Ernest S. Smith
-
Publication number: 20140148581Abstract: This disclosure relates to novel peptide agents, e.g., antibodies and antigen-binding fragments thereof, that bind hemagglutinin protein of influenza viruses, and methods of their use.Type: ApplicationFiled: October 10, 2013Publication date: May 29, 2014Applicant: VISTERRA, INC.Inventors: Zachary Shriver, Karthik Viswanathan, Vidya Subramanian, Sasisekharan Raguram
-
Publication number: 20140147439Abstract: A method of preparing an antibody suitable for use in a feline is provided. Also provided are chimeric and felinised antibodies which specifically bind to feline neuronal growth factor (NGF) and neutralise the ability of feline NGF to bind to the p75 or TrkA feline NGF receptor. The invention extends to nucleic acids encoding same and to methods of treating pain and arthritis in a feline using said antibodies and/or nucleic acids.Type: ApplicationFiled: May 8, 2012Publication date: May 29, 2014Inventor: David Gearing
-
Publication number: 20140147450Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth.Type: ApplicationFiled: November 6, 2013Publication date: May 29, 2014Applicant: ARGEN-X B.V.Inventors: Karen SILENCE, Peter ULRICHTS, Johannes Joseph Wilhelmus DE HAARD, Torsten DREIER, Michael John Scott SAUNDERS, Harald WAJANT, Sofie Maria Elvire GABRIELS, Mahan MOSHIR
-
Patent number: 8735546Abstract: Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided.Type: GrantFiled: August 2, 2011Date of Patent: May 27, 2014Assignee: AbbVie Inc.Inventors: Tariq Ghayur, Junjian Liu, Peter C. Isakson
-
Patent number: 8734795Abstract: LIGHT-targeting molecules (e.g., LIGHT fusion molecules), anti-HER2 antibody molecules, compositions, e.g., pharmaceutical compositions thereof, are disclosed. Methods of using these molecules to treat, prevent and/or diagnose hyperproliferative, e.g., neoplastic, diseases or conditions, including, but not limited to, cancer and metastasis are also provided.Type: GrantFiled: October 30, 2009Date of Patent: May 27, 2014Assignee: Biogen Idec MA Inc.Inventors: Xinzhong Wang, Veronique Bailly, Alexey Lugovskoy, Graham K. Farrington, Christilyn Graff, Scott Glaser